MacroGenics Inc. (NASDAQ:MGNX)’s share price rose 4.3% on Thursday . The company traded as high as $31.41 and last traded at $31.18, with a volume of 199,439 shares traded. The stock had previously closed at $29.89.

MGNX has been the subject of a number of research reports. Wedbush reiterated an “outperform” rating and set a $52.00 target price on shares of MacroGenics in a research report on Wednesday, May 18th. Zacks Investment Research upgraded shares of MacroGenics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, May 4th. Morgan Stanley reiterated a “hold” rating on shares of MacroGenics in a research report on Thursday, May 19th. TheStreet upgraded shares of MacroGenics from a “sell” rating to a “hold” rating in a research report on Friday, August 5th. Finally, BTIG Research reiterated a “buy” rating and set a $35.00 target price on shares of MacroGenics in a research report on Sunday, May 22nd. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $38.71.

The firm’s 50 day moving average price is $28.44 and its 200 day moving average price is $22.22. The company’s market cap is $1.09 billion.

MacroGenics (NASDAQ:MGNX) last issued its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $1.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $1.14. During the same period last year, the firm posted ($0.71) EPS. The business earned $80.67 million during the quarter, compared to analysts’ expectations of $27.22 million. MacroGenics’s quarterly revenue was up 1100.4% compared to the same quarter last year. On average, analysts anticipate that MacroGenics Inc. will post ($1.80) EPS for the current fiscal year.

In other MacroGenics news, VP Lynn Cilinski sold 5,000 shares of the business’s stock in a transaction dated Friday, May 27th. The stock was sold at an average price of $25.00, for a total value of $125,000.00. Following the completion of the transaction, the vice president now owns 6,923 shares of the company’s stock, valued at approximately $173,075. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Jon Marc Wigginton sold 20,000 shares of the business’s stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $30.78, for a total value of $615,600.00. Following the completion of the transaction, the senior vice president now directly owns 20,000 shares of the company’s stock, valued at approximately $615,600. The disclosure for this sale can be found here.

Other large investors have added to or reduced their stakes in the company. Cornerstone Capital Management Holdings LLC. raised its stake in MacroGenics by 87.9% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 44,743 shares of the biopharmaceutical company’s stock valued at $1,386,000 after buying an additional 20,929 shares during the last quarter. Marshall Wace LLP raised its stake in MacroGenics by 94.1% in the fourth quarter. Marshall Wace LLP now owns 93,709 shares of the biopharmaceutical company’s stock valued at $2,902,000 after buying an additional 45,422 shares during the last quarter. Finally, Jennison Associates LLC raised its stake in MacroGenics by 0.3% in the fourth quarter. Jennison Associates LLC now owns 267,408 shares of the biopharmaceutical company’s stock valued at $8,282,000 after buying an additional 909 shares during the last quarter.

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company operates through developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.